Press Release

  View printer-friendly version

« Back

West Introduces 1-3mL NovaPure® Plunger for Higher Volume Injections

New, high-quality plungers launched at the 2016 BIO International Convention

EXTON, Pa., June 7, 2016 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the availability of the 1-3mL NovaPure® plunger—an innovative, high-quality component for pre-filled delivery systems, designed to reduce particulate, ensure consistency of delivery and fit the changing needs of higher-volume injectable drug delivery systems. This new offering adds to West's current portfolio of NovaPure products, which includes the 1mL long NovaPure plunger and 13mm and 20mm NovaPure lyo and serum stoppers. West is showcasing the new 1-3mL NovaPure plunger among its portfolio of innovations in injectable drug packaging and delivery systems at booth #7544 at the 2016 BIO International Convention in San Francisco, Calif.

West Pharmaceutical Services logo. (PRNewsFoto/West)

"Over the past several years, the pharmaceutical industry has seen a steady rise in new biologic drugs coming onto the market for the treatment of chronic conditions, and these sophisticated therapies often have very specialized containment needs," said Karen Flynn, Senior Vice President & Chief Commercial Officer, West. "We are proud to introduce a packaging solution that can help protect the safety, efficacy and purity of these therapies."

West's 1-3mL NovaPure plungers are designed and manufactured using scientific, risk-mitigating Quality by Design (QbD) principles to ensure dimensional control and consistency, sub-visible and visible particulate control, and low parts per million (ppm) defect attributes. Additionally, with an optimized breakloose and glide force profile, 1-3mL NovaPure plungers are ideal to deliver consistent functional performance for auto-injector applications across various injection volumes, including as part of increasingly common 2.25mL injectable drug delivery systems.

"West is committed to helping its customers address both current and future healthcare challenges with a deep understanding of the complex needs of biologics," said Flynn. "We believe the new 1-3mL NovaPure plunger—backed by a body of scientific data and design history file—provides the performance and quality required to safely and effectively deliver these advanced drug products, helping our customers bring high-quality therapeutics to market more easily."

Additionally, as more biologics are being self-administered by patients at home, ease-of-use and convenience are increasingly important. By delivering a more consistent injection rate, West's 1-3 mL NovaPure plungers can help ensure patients receive accurate dosing of their treatment regimen.

For more information about the 1-3mL NovaPure plunger and other West products and services, please visit booth #7544 at the 2016 BIO International Convention or visit us online at

About West
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2015 sales of $1.4 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.

Forward-Looking Statements
Certain forward-looking statements are included in this release. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that West's 1-3 mL NovaPure plungers will achieve any level of commercial success. These forward-looking statements involve a number of risks and uncertainties. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2015.

Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

West and the diamond logo, NovaPure and By your side for a healthier world™ are registered trademarks or trademarks of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.

Media Contact:
Tiffany Burke
Global Communications
+ 1-610-594-3231

Logo -

To view the original version on PR Newswire, visit:

SOURCE West Pharmaceutical Services, Inc.